Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China’s National Medical Products Administration (NMPA) has approved its injectable recaticimab to proceed into a Phase 3 clinical trial for a new indication: reducing the risk of stroke recurrence in adult patients with intracranial atherosclerotic stenosis (ICAS). The clearance marks a strategic expansion of the PCSK9 inhibitor from lipid management into cerebrovascular disease prevention.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval – Phase 3, new indication |
| Product | Recaticimab injection (PCSK9‑targeted monoclonal antibody) |
| Proposed Indication | Reduction of stroke recurrence risk in adult patients with intracranial atherosclerotic stenosis |
| Announcement Date | 16 Sep 2026 |
| Existing Approval | Hypercholesterolemia and mixed dyslipidemia in adults (Jan 2025) |
| Next Steps | Phase 3 trial initiation and enrollment; trial design details not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Recaticimab, an injectable monoclonal antibody independently developed by Hengrui Pharma.
- Target: PCSK9 (proprotein convertase subtilisin/kexin type 9), a key regulator of cholesterol metabolism.
- Mechanism: Inhibits the binding of PCSK9 to the low‑density lipoprotein receptor (LDLR), increasing the number of LDLRs available to clear LDL from the bloodstream and thereby reducing LDL‑C levels.
- Commercial Status: First approved by the NMPA in January 2025 for adult patients with hypercholesterolemia and mixed dyslipidemia.
- New Direction: Label expansion toward outcome‑driven cerebrovascular prevention — stroke recurrence reduction in ICAS patients.
Phase 3 Trial – Design & Clinical Context
- Trial Design: Endpoints, sample size, and enrollment timeline not disclosed in the company announcement.
- Disease Background: Intracranial atherosclerotic stenosis is a leading cause of ischemic stroke, with a disproportionately high prevalence among Asian populations, and carries a substantial risk of recurrent stroke despite standard medical therapy.
- Clinical Rationale: Elevated LDL‑C is a well‑established driver of atherosclerotic progression; intensive lipid lowering via PCSK9 inhibition provides the mechanistic basis for testing recaticimab in stroke secondary prevention.
- Significance: A successful Phase 3 program would position recaticimab among the first PCSK9 inhibitors evaluated specifically for ICAS‑related stroke recurrence in China.
Market Impact & Outlook
- Indication Expansion Strategy: The move extends recaticimab’s addressable population beyond dyslipidemia into the much larger stroke secondary‑prevention market, potentially transforming it from a lipid‑lowering agent into a cardiovascular‑outcomes asset.
- China Stroke Landscape: Stroke remains a leading cause of death and disability in China, and ICAS‑related events represent a significant unmet need where additional preventive therapies are actively sought.
- Competitive Edge: As a domestically developed PCSK9 monoclonal antibody already on the market, Hengrui can leverage its established commercial infrastructure and clinical development experience in the crowded PCSK9 class.
- Financial Impact: Revenue implications of the new indication are not disclosed; Phase 3 outcome data will be required before any commercial projections can be assessed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical trial outcomes, and commercial expectations for recaticimab. Actual results may differ materially due to risks including trial enrollment and execution, clinical efficacy and safety findings, subsequent regulatory review requirements, and competitive dynamics in the PCSK9 inhibitor market.-Fineline Info & Tech
